Information scientifique - Références

Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y.
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Anticancer Res. 2004 Sep-Oct;24(5A):2783-840. Review.

Augustin HG.
Translating angiogenesis research into the clinic: the challenges ahead.
Br J Radiol. 2003;76 Spec No 1:S3-10. Review.

Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E.
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Ann Oncol. 2002 Aug;13(8):1259-63.

Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Clin Cancer Res. 2002 Apr;8(4):1242-50.

Bellamy WT.
Vascular endothelial growth factor as a target opportunity in hematological malignancies.
Curr Opin Oncol. 2002 Nov;14(6):649-56. Review.

Berbari P, Thibodeau A, Germain L, Saint-Cyr M, Gaudreau P, Elkhouri S, Dupont E, Garrel DR, Elkouri S, El-Khouri S.
Antiangiogenic effects of the oral administration of liquid cartilage extract in humans.
J Surg Res. 1999 Nov;87(1):108-13. Erratum in: J Surg Res 2000 Apr;89(2):197.

Bernas GC.
Angiotherapeutics from natural products: from bench to clinics?
Clin Hemorheol Microcirc. 2003;29(3-4):199-203. Review.

Bian XW, Chen JH, Jiang XF, Bai JS, Wang QL, Zhang X.
Angiogenesis as an immunopharmacologic target in inflammation and cancer.
Int Immunopharmacol. 2004 Nov;4(12):1537-47.

Boivin D, Provencal M, Gendron S, Ratel D, Demeule M, Gingras D, Beliveau R.
Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain.
Arch Biochem Biophys. 2004 Nov 15;431(2):197-206.

Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R.
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.
Mol Cancer Ther. 2002 Aug;1(10):795-802.

Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M.
New drugs for treatment of multiple myeloma.
Lancet Oncol. 2004 Jul;5(7):430-42. Review.

Bukowski RM.
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma.
Expert Opin Investig Drugs. 2003 Aug;12(8):1403-11. Review.

Carmeliet P.
Manipulating angiogenesis in medicine.
J Intern Med. 2004 May;255(5):538-61. Review.

Carmeliet P.
Angiogenesis in health and disease.
Nat Med. 2003 Jun;9(6):653-60. Review.

Chen HX.
Expanding the clinical development of bevacizumab.
Oncologist. 2004;9 Suppl 1:27-35. Review.

Cho J, Kim Y.
Sharks: a potential source of antiangiogenic factors and tumor treatments.
Mar Biotechnol (NY). 2002 Dec;4(6):521-5.

Costa C, Soares R, Schmitt F.
Angiogenesis: now and then.
APMIS. 2004 Jul-Aug;112(7-8):402-12. Review.

Couzin J.
Beefed-up NIH center probes unconventional therapies.
Science. 1998 Dec 18;282(5397):2175-6.

Creamer D, Sullivan D, Bicknell R, Barker J.
Angiogenesis in psoriasis.
Angiogenesis. 2002;5(4):231-6. Review

Davidson B, Reich R, Risberg B, Nesland JM.
The biological role and regulation of matrix metalloproteinases (MMP) in cancer.
Arkh Patol. 2002 May-Jun;64(3):47-53. Review.

Demeule M, Michaud-Levesque J, Annabi B, Gingras D, Boivin D, Jodoin J, Lamy S, Bertrand Y, Beliveau R.
Green tea catechins as novel antitumor and antiangiogenic compounds.
Curr Med Chem Anti-Canc Agents. 2002 Jul;2(4):441-63. Review.

Dorai T, Aggarwal BB.
Role of chemopreventive agents in cancer therapy.
Cancer Lett. 2004 Nov 25;215(2):129-40. Review.

Dredge K.
AE-941 (AEterna).
Curr Opin Investig Drugs. 2004 Jun;5(6):668-77. Review.

Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marme D, Unger C.
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Anticancer Res. 2004 May-Jun;24(3a):1759-63.

Dupont E, Wang B, Mamelak AJ, Howell BG, Shivji G, Zhuang L, Dimitriadou V, Falardeau P, Sauder DN.
Modulation of the Contact Hypersensitivity Response by AE-941 (Neovastat), a Novel Antiangiogenic Agent.
J Cutan Med Surg. 2003 Feb 10

Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T, Alaoui-Jamali MA.
Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue.
Clin Exp Metastasis. 2002;19(2):145-53.

Dupont E, Savard PE, Jourdain C, Juneau C, Thibodeau A, Ross N, Marenus K, Maes DH, Pelletier G, Sauder DN.
Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis.
J Cutan Med Surg. 1998 Jan;2(3):146-52.

Eskens FA.
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Br J Cancer. 2004 Jan 12;90(1):1-7. Review.

Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E.
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
Semin Oncol. 2001 Dec;28(6):620-5. Review.

Feron O.
Targeting the tumor vascular compartment to improve conventional cancer therapy.
Trends Pharmacol Sci. 2004 Oct;25(10):536-42. Review.

Ferrara N.
Vascular endothelial growth factor as a target for anticancer therapy.
Oncologist. 2004;9 Suppl 1:2-10. Review.

Folkman J.
Endogenous angiogenesis inhibitors.
APMIS. 2004 Jul-Aug;112(7-8):496-507. Review.

Folkman J, Kalluri R.
Cancer without disease.
Nature. 2004 Feb 26;427(6977):787.

Folkman J.
Fundamental concepts of the angiogenic process.
Curr Mol Med. 2003 Nov;3(7):643-51. Review.

Folkman J.
Angiogenesis inhibitors: a new class of drugs.
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33. Review.

Folkman J.
Angiogenesis and apoptosis.
Semin Cancer Biol. 2003 Apr;13(2):159-67. Review.

Gingras D, Nyalendo C, Di Tomasso G, Annabi B, Beliveau R.
Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent.
Biochem Biophys Res Commun. 2004 Jul 16;320(1):205-12.

Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R.
Neovastat--a novel antiangiogenic drug for cancer therapy.
Anticancer Drugs. 2003 Feb;14(2):91-6. Review.

Gingras D, Batist G, Beliveau R.
AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.
Expert Rev Anticancer Ther. 2001 Oct;1(3):341-7.

Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R.
Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.
Anticancer Res. 2001 Jan-Feb;21(1A):145-55.

Gingras D, Renaud A, Mousseau N, Beliveau R.
hark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?
Cancer Metastasis Rev. 2000;19(1-2):83-6. Review.

Hammerness P, Ulbricht C, Barrette EP, Boon H, Szapary P, Sollars D, Smith M, Tsourounis C, Bent S, Basch E.
Shark cartilage monograph: a clinical decision support tool.
J Herb Pharmacother. 2002;2(2):71-93.

Jain RK.
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Science. 2005 Jan 7;307(5706):58-62. Review.

Jain RK.
Molecular regulation of vessel maturation.
Nat Med. 2003 Jun;9(6):685-93. Review.

Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ.
Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
Brain Res Brain Res Rev. 2004 Jul;45(3):143-63. Review.

Kerbel RS, Kamen BA.
The anti-angiogenic basis of metronomic chemotherapy.
Nat Rev Cancer. 2004 Jun;4(6):423-36. Review.

Kerbel RS.
Antiangiogenic drugs and current strategies for the treatment of lung cancer.
Semin Oncol. 2004 Feb;31(1 Suppl 1):54-60. Review.

Kim RW, Heier JS.
Innovative treatments for exudative age-related macular degeneration.
Int Ophthalmol Clin. 2004 Fall;44(4):41-50. Review.

Kralovec JA, Guan Y, Metera K, Carr RI.
Immunomodulating principles from shark cartilage. Part 1. Isolation and biological assessment in vitro.
Int Immunopharmacol. 2003 May;3(5):657-69.

Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E.
Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer.
Clin Lung Cancer. 2003 Jan;4(4):231-6.

Lin EY, Pollard JW.
Role of infiltrated leucocytes in tumour growth and spread.
Br J Cancer. 2004 Jun 1;90(11):2053-8. Review.

Liu M, Regillo CD.
A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials.
Curr Opin Ophthalmol. 2004 Jun;15(3):221-6. Review.

Losso, JN
Preventing degenerative diseases by anti-angiogenic functional foods.
Food Technology 2002 June, 56(6):78-88.

Luttun A, Carmeliet P.
Angiogenesis and lymphangiogenesis: highlights of the past year.
Curr Opin Hematol. 2004 Jul;11(4):262-71. Review.

Marwick C.
Natural compounds show antiangiogenic activity.
J Natl Cancer Inst. 2001 Nov 21;93(22):1685.

Mazitschek R, Giannis A.
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
Curr Opin Chem Biol. 2004 Aug;8(4):432-41. Review.

McCarty MF.
A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer.
Med Hypotheses. 2003 Jul;61(1):1-15.

Moehler TM, Hillengass J, Goldschmidt H, Ho AD.
Antiangiogenic therapy in hematologic malignancies.
Curr Pharm Des. 2004;10(11):1221-34. Review.

Mook OR, Frederiks WM, Van Noorden CJ.
The role of gelatinases in colorectal cancer progression and metastasis.
Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89. Review.

Moyad MA.
Results and lessons from clinical trials using dietary supplements for cancer: direct and indirect investigations.
Semin Urol Oncol. 2001 Nov;19(4):232-46. Review.

Muehlbauer PM.
Anti-angiogenesis in cancer therapy.
Semin Oncol Nurs. 2003 Aug;19(3):180-92. Review.

Negrier S, Mejean A, Oudard S, Escudier B.
Metastatic kidney cancer: new therapeutic approaches
Prog Urol. 2002 Sep;12(4):703-8. Review. French.

Papetti M, Herman IM.
Mechanisms of normal and tumor-derived angiogenesis.
Am J Physiol Cell Physiol. 2002 May;282(5):C947-70. Review.

Ramnath N, Creaven PJ.
Matrix metalloproteinase inhibitors.
Curr Oncol Rep. 2004 Mar;6(2):96-102. Review.

Ribatti D.
The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review.
Br J Haematol. 2005 Feb;128(3):303-9.

Roudebush P, Davenport DJ, Novotny BJ.
The use of nutraceuticals in cancer therapy.
Vet Clin North Am Small Anim Pract. 2004 Jan;34(1):249-69, viii. Review.

Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E.
Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis.
J Am Acad Dermatol. 2002 Oct;47(4):535-41.

Shepherd FA, Sridhar SS.
Angiogenesis inhibitors under study for the treatment of lung cancer.
Lung Cancer. 2003 Aug;41 Suppl 1:S63-72. Review.

Siemann DW, Chaplin DJ, Horsman MR.
Vascular-targeting therapies for treatment of malignant disease.
Cancer. 2004 Jun 15;100(12):2491-9. Review.

Soria JC, Fayette J, Armand JP.
Molecular targeting: targeting angiogenesis in solid tumors.
Ann Oncol. 2004;15 Suppl 4:iv223-7. Review.

Sorsa T, Tjaderhane L, Salo T.
Matrix metalloproteinases (MMPs) in oral diseases.
Oral Dis. 2004 Nov;10(6):311-8. Review.

Sridhar SS, Shepherd FA.
Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.
Lung Cancer. 2003 Dec;42 Suppl 1:S81-91. Review.

Stasi R, Amadori S.
The role of angiogenesis in hematologic malignancies.
J Hematother Stem Cell Res. 2002 Feb;11(1):49-68. Review.

Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE.
Current methods for assaying angiogenesis in vitro and in vivo.
Int J Exp Pathol. 2004 Oct;85(5):233-48. Review

Tandle A, Blazer DG 3rd, Libutti SK.
Antiangiogenic gene therapy of cancer: recent developments.
J Transl Med. 2004 Jun 25;2(1):22.

Walsh DA.
Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes.
Curr Opin Rheumatol. 2004 Sep;16(5):609-15. Review.

Weber MH, Lee J, Orr FW
The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
Int J Oncol. 2002 Feb;20(2):299-303.

Whelan CJ.
Metalloprotease inhibitors as anti-inflammatory agents: an evolving target?
Curr Opin Investig Drugs. 2004 May;5(5):511-6. Review.